Ezek Mathew
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ezek Mathew has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Rob Dickerman
Systems Science, University of North Texas Health, Fort Worth, TX 76107, USA
3 shared publications - Luke C. Cooksey
Department of Microbiology, Immunology and Genetics, University of North Texas Health, Fort Worth, TX 76107, USA
2 shared publications - Nathan Jones
Department of Microbiology and Immunology, The University of North Texas Health Science Center, 3500 Camp Bowie Blvd, Fort Worth, TX 76107, USA
2 shared publications - Nirupama Sabnis
Department of Microbiology, Immunology and Genetics, University of North Texas Health, Fort Worth, TX 76107, USA
2 shared publications - Porunelloor Abraham Mathew
Department of Microbiology, Immunology and Genetics, University of North Texas Health, Fort Worth, TX 76107, USA
2 shared publications Rob Dickerman
Department of Neurosurgery, The Medical City of Frisco, Frisco, Texas
2 shared publications
Latest Publications
- Open Access
- 30 April 2026
- Published by MDPI AG in Brain Sciences
- Vol. 16 (5) , 487
Evolving Landscape of Glioblastoma Research: Integrating Therapeutic Advances and Diagnostic Frontiers
Glioblastoma (GB) remains the most aggressive primary brain malignancy, with the Stupp regimen persisting as the standard of care for nearly two decades despite poor survival outcomes. This review was synthesized by extensively reviewing and analyzing the literature from PubMed, Scopus, and Web of Science to evaluate the emerging promising therapeutic and diagnostic strategies for combating GB. Results indicate significant progress in molecularly targeted therapies, biomimetic nanocarriers, and advanced radiotherapy. While immunotherapeutic approaches, such as checkpoint inhibitors and vaccines, show variable clinical success, the integration of bioinformatics and machine learning has significantly enhanced treatment response prediction. Furthermore, advances in radiomics and molecular imaging have improved the differentiation between true tumor progression and pseudoprogression, potentially reducing invasive diagnostic requirements. Additionally, other emerging and investigational adjuvant therapeutic approaches have shown promise. We conclude that, while multimodal strategies integrating molecular and computational approaches offer a path toward personalized GB management, significant barriers—namely tumor heterogeneity and the blood–brain barrier—persist. Future research must prioritize precision-based combinatorial models to successfully translate these preclinical advancements into improved clinical outcomes for patients.
- 30 April 2026
- Published by MDPI AG in Brain Sciences
- Vol. 16 (5) , 487
Open AccessEvolving Landscape of Glioblastoma Research: Integrating Therapeutic Advances and Diagnostic Frontiers
Glioblastoma (GB) remains the most aggressive primary brain malignancy, with the Stupp regimen persisting as the standard of care for nearly two decades despite poor survival outcomes. This review was synthesized by extensively reviewing and analyzing the literature from PubMed, Scopus, and Web of Science to evaluate the emerging promising therapeutic and diagnostic strategies for combating GB. Results indicate significant progress in molecularly targeted therapies, biomimetic nanocarriers, and advanced radiotherapy. While immunotherapeutic approaches, such as checkpoint inhibitors and vaccines, show variable clinical success, the integration of bioinformatics and machine learning has significantly enhanced treatment response prediction. Furthermore, advances in radiomics and molecular imaging have improved the differentiation between true tumor progression and pseudoprogression, potentially reducing invasive diagnostic requirements. Additionally, other emerging and investigational adjuvant therapeutic approaches have shown promise. We conclude that, while multimodal strategies integrating molecular and computational approaches offer a path toward personalized GB management, significant barriers—namely tumor heterogeneity and the blood–brain barrier—persist. Future research must prioritize precision-based combinatorial models to successfully translate these preclinical advancements into improved clinical outcomes for patients.
- Open Access
Cell-Surface PCNA Is Co-Expressed with Biomarkers of Stemness and Immunosuppression in Glioblastoma
Background/Objectives: Glioblastoma (GBM) is a lethal form of primary brain tumor. There has been minimal improvement in overall GBM survival in recent years. To increase survival in patients with GBM, it is important to study novel GBM molecular antigens to form the basis of better diagnostics, prognostic measures, and therapeutic advancements. Our goal is to find more robust GBM-specific antigenic biomarkers to eventually improve GBM outcomes. Here, we initiated an investigation into cell-surface PCNA (csPCNA), a potential GBM biomarker and antigenic target. Methods: We utilized flow cytometry, imaging flow cytometry, and cell-surface Western blot to identify the expression of csPCNA on GBM cell lines (LN-229, LN-18) and a primary patient-derived tumor specimen. We then employed flow cytometry to study the associative co-expression of csPCNA with other biomarkers of GBM stem cells (CD44, CD49f) and GBM immunosuppression (PD-L1, TGFβRII). Results: We elucidated that LN-229, LN-18, and the primary GBM patient cells express csPCNA. We found that csPCNA is co-expressed with CD44, CD49f, PD-L1, and TGFβRII on the primary patient-derived GBM specimen. Conclusions: Our findings that csPCNA is expressed in GBM and is co-expressed with stem cell and immunosuppressive biomarkers indicate that csPCNA may be a potentially useful clinical–pathological biomarker for GBM stemness and immunosuppression.
Open AccessCell-Surface PCNA Is Co-Expressed with Biomarkers of Stemness and Immunosuppression in Glioblastoma
Background/Objectives: Glioblastoma (GBM) is a lethal form of primary brain tumor. There has been minimal improvement in overall GBM survival in recent years. To increase survival in patients with GBM, it is important to study novel GBM molecular antigens to form the basis of better diagnostics, prognostic measures, and therapeutic advancements. Our goal is to find more robust GBM-specific antigenic biomarkers to eventually improve GBM outcomes. Here, we initiated an investigation into cell-surface PCNA (csPCNA), a potential GBM biomarker and antigenic target. Methods: We utilized flow cytometry, imaging flow cytometry, and cell-surface Western blot to identify the expression of csPCNA on GBM cell lines (LN-229, LN-18) and a primary patient-derived tumor specimen. We then employed flow cytometry to study the associative co-expression of csPCNA with other biomarkers of GBM stem cells (CD44, CD49f) and GBM immunosuppression (PD-L1, TGFβRII). Results: We elucidated that LN-229, LN-18, and the primary GBM patient cells express csPCNA. We found that csPCNA is co-expressed with CD44, CD49f, PD-L1, and TGFβRII on the primary patient-derived GBM specimen. Conclusions: Our findings that csPCNA is expressed in GBM and is co-expressed with stem cell and immunosuppressive biomarkers indicate that csPCNA may be a potentially useful clinical–pathological biomarker for GBM stemness and immunosuppression.
- Open Access
Unilateral to Bilateral Lumbosacral Plexopathy After Radiation Therapy: A Case Report
Radiation therapy (RT) has been one of the standard treatments for prostate cancer; however, its potential impact on nearby neural structures, such as the lumbosacral plexus (LSP), is often overlooked. The lack of contouring in treatment plans has led to unintended consequences. Radiation-induced lumbosacral plexopathy (RILSP) is a rare but serious complication that presents with progressive lower extremity sensory changes and weakness, mimicking radiculopathy. We report the case of a 66-year-old male who developed bilateral lower extremity neurological deficits post-pelvic radiation for prostate cancer. Radiographically, no compressive lesions were found, and the Electromyography (EMG) revealed involvement of nerves inconsistent with radiculopathy. This led to the diagnosis of RILSP. This case highlights the importance of recognition of RILSP in contrast to radiculopathy in patients with unexplained neurological symptoms after pelvic RT. This highlights the importance of incorporating the LSP as an organ at risk while planning for RT and reviewing retrospectively the dosimetry. It also emphasizes the need for improved contouring of LSP in radiation planning to minimize adverse effects. This sentiment is reflected in the literature, along with the consensus that more research is needed to address the true rate of RILSP.
Open AccessUnilateral to Bilateral Lumbosacral Plexopathy After Radiation Therapy: A Case Report
Radiation therapy (RT) has been one of the standard treatments for prostate cancer; however, its potential impact on nearby neural structures, such as the lumbosacral plexus (LSP), is often overlooked. The lack of contouring in treatment plans has led to unintended consequences. Radiation-induced lumbosacral plexopathy (RILSP) is a rare but serious complication that presents with progressive lower extremity sensory changes and weakness, mimicking radiculopathy. We report the case of a 66-year-old male who developed bilateral lower extremity neurological deficits post-pelvic radiation for prostate cancer. Radiographically, no compressive lesions were found, and the Electromyography (EMG) revealed involvement of nerves inconsistent with radiculopathy. This led to the diagnosis of RILSP. This case highlights the importance of recognition of RILSP in contrast to radiculopathy in patients with unexplained neurological symptoms after pelvic RT. This highlights the importance of incorporating the LSP as an organ at risk while planning for RT and reviewing retrospectively the dosimetry. It also emphasizes the need for improved contouring of LSP in radiation planning to minimize adverse effects. This sentiment is reflected in the literature, along with the consensus that more research is needed to address the true rate of RILSP.
- Open Access
- 10 September 2025
- Published by MDPI AG in International Journal of Translational Medicine
- Vol. 5 (3) , 42
Evaluating Leucine, Isoleucine, and Valine Ratios in Mixed Cortical Cell Cultures Following Cortical Trauma: An In Vitro Assessment
Background/Objectives: Traumatic brain injury (TBI) remains the most common cause of morbidity and mortality in adolescents and adults. Although numerous animal and human studies have demonstrated the beneficial effects of branched-chain amino acids (BCAA) treatment on various models of brain injury, the optimal concentration and mechanism of action have not been elucidated. Methods: Based on our prior work, we hypothesized that a 2:1:1 ratio of BCAAs promotes neuronal regrowth and repair. Using in vitro mixed cortical cultures (composed of CNS cells, including neuronal and glial cells), we recapitulated the mechanical damage induced by TBI using the scratch assay model. We evaluated various concentrations of BCAA to promote the regrowth of CNS cells after mechanical damage. Results: A 2:1:1 ratio of leucine: isoleucine: valine was observed to yield superior regrowth rates at the 48 h time point across various concentrations when compared to a 1:1:1 ratio and even a 4:1:1 ratio. In addition, both 2:1:1 and 4:1:1 ratios offered multiple instances of accelerated regrowth, where less than 5% of the wound remained unhealed. Conclusions: The importance of leucine ratios in the context of BCAA treatment for TBI was demonstrated by the superior CNS cell regrowth offered by the 2:1:1 ratio.
- 10 September 2025
- Published by MDPI AG in International Journal of Translational Medicine
- Vol. 5 (3) , 42
Open AccessEvaluating Leucine, Isoleucine, and Valine Ratios in Mixed Cortical Cell Cultures Following Cortical Trauma: An In Vitro Assessment
Background/Objectives: Traumatic brain injury (TBI) remains the most common cause of morbidity and mortality in adolescents and adults. Although numerous animal and human studies have demonstrated the beneficial effects of branched-chain amino acids (BCAA) treatment on various models of brain injury, the optimal concentration and mechanism of action have not been elucidated. Methods: Based on our prior work, we hypothesized that a 2:1:1 ratio of BCAAs promotes neuronal regrowth and repair. Using in vitro mixed cortical cultures (composed of CNS cells, including neuronal and glial cells), we recapitulated the mechanical damage induced by TBI using the scratch assay model. We evaluated various concentrations of BCAA to promote the regrowth of CNS cells after mechanical damage. Results: A 2:1:1 ratio of leucine: isoleucine: valine was observed to yield superior regrowth rates at the 48 h time point across various concentrations when compared to a 1:1:1 ratio and even a 4:1:1 ratio. In addition, both 2:1:1 and 4:1:1 ratios offered multiple instances of accelerated regrowth, where less than 5% of the wound remained unhealed. Conclusions: The importance of leucine ratios in the context of BCAA treatment for TBI was demonstrated by the superior CNS cell regrowth offered by the 2:1:1 ratio.
- Open Access
- 21 July 2025
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 10 (30) , 32968-32986
I-GAT: Interpretable Graph Attention Networks for Ligand Optimization
Designing selective and potent ligands for target receptors remains a significant challenge in drug discovery. Computational approaches, particularly advancements in machine learning (ML), offer transformative potential in addressing this challenge. In this study, our goal was to develop a composite ML model capable of predicting ligand selectivity and potency with high accuracy while also providing interpretable insights to guide ligand optimization. To achieve this goal, we first compiled a data set of 757 ligands, including metabotropic glutamate receptor subtype 2 (mGlu2) negative allosteric modulators (NAMs), metabotropic glutamate receptor subtype 3 (mGlu3) NAMs, and nonselective dual mGlu2/3 NAMs from patent filings. In three phases, we developed an ML model with Interpretable Graph Attention (I-GAT) networks for drug optimization. In phase 1, we created a composite model that can accurately predict selectivity and potency metrics by integrating graph architecture with transfer learning methodologies. Our model demonstrated over 97% accuracy in predicting ligand NAM selectivity and upward of 78% accuracy in potency prediction. Phase 2 used attention mechanisms to enhance model interpretability, effectively illuminating the “black box” of ML decision-making. Finally, in phase 3, we utilized attention gradients to intelligently modify known ligands, leading to the design of a novel ligand with predicted superior properties compared to the original. Our approach demonstrates the dual benefits of predictive accuracy and atom-level interpretability, offering a powerful framework for ligand design. When applied to external data, our model matched and, in some cases, exceeded the performance of current state-of-the-art chemistry-focused ML models across multiple data sets. Ultimately, our model has the potential to be adapted to other receptors and molecular properties, paving the way for a more efficient and targeted drug discovery process.
- 21 July 2025
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 10 (30) , 32968-32986
Open AccessI-GAT: Interpretable Graph Attention Networks for Ligand Optimization
Designing selective and potent ligands for target receptors remains a significant challenge in drug discovery. Computational approaches, particularly advancements in machine learning (ML), offer transformative potential in addressing this challenge. In this study, our goal was to develop a composite ML model capable of predicting ligand selectivity and potency with high accuracy while also providing interpretable insights to guide ligand optimization. To achieve this goal, we first compiled a data set of 757 ligands, including metabotropic glutamate receptor subtype 2 (mGlu2) negative allosteric modulators (NAMs), metabotropic glutamate receptor subtype 3 (mGlu3) NAMs, and nonselective dual mGlu2/3 NAMs from patent filings. In three phases, we developed an ML model with Interpretable Graph Attention (I-GAT) networks for drug optimization. In phase 1, we created a composite model that can accurately predict selectivity and potency metrics by integrating graph architecture with transfer learning methodologies. Our model demonstrated over 97% accuracy in predicting ligand NAM selectivity and upward of 78% accuracy in potency prediction. Phase 2 used attention mechanisms to enhance model interpretability, effectively illuminating the “black box” of ML decision-making. Finally, in phase 3, we utilized attention gradients to intelligently modify known ligands, leading to the design of a novel ligand with predicted superior properties compared to the original. Our approach demonstrates the dual benefits of predictive accuracy and atom-level interpretability, offering a powerful framework for ligand design. When applied to external data, our model matched and, in some cases, exceeded the performance of current state-of-the-art chemistry-focused ML models across multiple data sets. Ultimately, our model has the potential to be adapted to other receptors and molecular properties, paving the way for a more efficient and targeted drug discovery process.
- Open Access
Setting the Stage for Branched-Chain Amino Acids Use in Neurological Pathologies: Does a Single Oral Dose Provide Hours of Elevated Systemic Levels?
Background: Recent studies have demonstrated that branched-chain amino acids are neuroprotective and neurorestorative. Branched-chain amino acid supplements are now being recommended to be taken before contact sports to reduce concussions. While peaks and troughs in branched-chain amino acids have previously been reported in hospital settings, the metabolism of a single recommended dose of over-the-counter branched-chain amino acids has yet to be elucidated. Methods: We analyzed a patented branched-chain amino acid product to assess its metabolism in 10 healthy adults. Results: Over the defined time points, measured levels of branched-chain amino acids remained significantly elevated when compared to the physiological baseline. The elevations in measured plasma levels indicate that a single oral dose is a viable intake option for increasing levels of branched-chain amino acids. Conclusions: This information can be leveraged to better plan branched-chain amino acid-based treatment doses in order to treat pathologies such as brain injury.
Open AccessSetting the Stage for Branched-Chain Amino Acids Use in Neurological Pathologies: Does a Single Oral Dose Provide Hours of Elevated Systemic Levels?
Background: Recent studies have demonstrated that branched-chain amino acids are neuroprotective and neurorestorative. Branched-chain amino acid supplements are now being recommended to be taken before contact sports to reduce concussions. While peaks and troughs in branched-chain amino acids have previously been reported in hospital settings, the metabolism of a single recommended dose of over-the-counter branched-chain amino acids has yet to be elucidated. Methods: We analyzed a patented branched-chain amino acid product to assess its metabolism in 10 healthy adults. Results: Over the defined time points, measured levels of branched-chain amino acids remained significantly elevated when compared to the physiological baseline. The elevations in measured plasma levels indicate that a single oral dose is a viable intake option for increasing levels of branched-chain amino acids. Conclusions: This information can be leveraged to better plan branched-chain amino acid-based treatment doses in order to treat pathologies such as brain injury.
- Open Access
- 12 December 2022
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery: Case Lessons
- Vol. 4 (24)
Transverse myelitis after Johnson & Johnson COVID-19 vaccine: illustrative case
BACKGROUND: Transverse myelitis is a rare neurological occurrence with varied presentation. Imaging is necessary to properly diagnose this condition; however, identifying the cause of this condition may often be difficult. OBSERVATIONS: An otherwise healthy patient presented to the clinic with peculiar neurological symptoms without an obvious underlying cause. Imaging evidenced no significant structural defects but did lead to discovery of cord enhancement compatible with a diagnosis of transverse myelitis. Corticosteroid treatment was initiated rapidly to address this pathology, and the patient recovered without deficits. To identify the underlying cause, patient medical history was reviewed thoroughly and compared with existing literature. Previous tuberculosis infection could be a less likely cause of the neurological symptoms. However, recent vaccination with the Johnson & Johnson coronavirus disease 2019 (COVID-19) vaccine could be a more likely cause of the transverse myelitis, which has been rarely reported. LESSONS: Transverse myelitis after COVID-19 infection has been an escalating phenomenon. However, transverse myelitis after COVID-19 vaccination is a rare occurrence that is also on the rise. Given the increased rates of vaccination, transverse myelitis should not be overlooked as a potential pathology, due to the severity of neurological impairment if this condition is not treated rapidly.
- 12 December 2022
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery: Case Lessons
- Vol. 4 (24)
Open AccessTransverse myelitis after Johnson & Johnson COVID-19 vaccine: illustrative case
BACKGROUND: Transverse myelitis is a rare neurological occurrence with varied presentation. Imaging is necessary to properly diagnose this condition; however, identifying the cause of this condition may often be difficult. OBSERVATIONS: An otherwise healthy patient presented to the clinic with peculiar neurological symptoms without an obvious underlying cause. Imaging evidenced no significant structural defects but did lead to discovery of cord enhancement compatible with a diagnosis of transverse myelitis. Corticosteroid treatment was initiated rapidly to address this pathology, and the patient recovered without deficits. To identify the underlying cause, patient medical history was reviewed thoroughly and compared with existing literature. Previous tuberculosis infection could be a less likely cause of the neurological symptoms. However, recent vaccination with the Johnson & Johnson coronavirus disease 2019 (COVID-19) vaccine could be a more likely cause of the transverse myelitis, which has been rarely reported. LESSONS: Transverse myelitis after COVID-19 infection has been an escalating phenomenon. However, transverse myelitis after COVID-19 vaccination is a rare occurrence that is also on the rise. Given the increased rates of vaccination, transverse myelitis should not be overlooked as a potential pathology, due to the severity of neurological impairment if this condition is not treated rapidly.
- Open Access
- 4 March 2022
- Published by Elsevier in Cerebral Circulation - Cognition and Behavior
- Vol. 3, 100126
Subjective cognitive complaints and cardiovascular risk factors in older Mexican Americans: A cross-sectional study.
- 4 March 2022
- Published by Elsevier in Cerebral Circulation - Cognition and Behavior
- Vol. 3, 100126
Open AccessSubjective cognitive complaints and cardiovascular risk factors in older Mexican Americans: A cross-sectional study.
- Open Access
- 10 May 2021
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery: Case Lessons
- Vol. 1 (19) , CASE20113
Right hemidiaphragmatic paralysis after cervical transforaminal epidural steroid injection: illustrative case
BACKGROUND: Cervical radiculopathy is a common cause of neck pain, with radiation into the upper extremity in a dermatomal pattern. Corticosteroid injection is a conservative management option with a low risk of major adverse events. No reviewed literature or case reports have implicated phrenic nerve injury secondary to cervical transforaminal epidural steroid injection (CTFESI). OBSERVATIONS: A 45-year-old man with severe right C6 radiculopathy secondary to a large right-sided C5–6 herniated intervertebral disc presented to the pain management clinic, where he received a right-sided C6 CTFESI. An hour after injection, the patient experienced shortness of breath, which was found to be caused by right diaphragmatic paralysis. The patient underwent a C5–6 anterior cervical discectomy and fusion, which provided complete relief of his radicular symptoms. However, the right hemidiaphragmatic paralysis remained at the 1-year postoperative visit. LESSONS: Thorough literature review showed no established explanations for phrenic nerve injury after CTFESI. In this study, the authors explored the suspected mechanisms of possible injury to the phrenic nerve. Epidural corticosteroid injection is considered to be a safe option for conservative management of cervical radiculopathy. This study unveiled a unique and important adverse event that should be considered before a patient receives CTFESI.
- 10 May 2021
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery: Case Lessons
- Vol. 1 (19) , CASE20113
Open AccessRight hemidiaphragmatic paralysis after cervical transforaminal epidural steroid injection: illustrative case
BACKGROUND: Cervical radiculopathy is a common cause of neck pain, with radiation into the upper extremity in a dermatomal pattern. Corticosteroid injection is a conservative management option with a low risk of major adverse events. No reviewed literature or case reports have implicated phrenic nerve injury secondary to cervical transforaminal epidural steroid injection (CTFESI). OBSERVATIONS: A 45-year-old man with severe right C6 radiculopathy secondary to a large right-sided C5–6 herniated intervertebral disc presented to the pain management clinic, where he received a right-sided C6 CTFESI. An hour after injection, the patient experienced shortness of breath, which was found to be caused by right diaphragmatic paralysis. The patient underwent a C5–6 anterior cervical discectomy and fusion, which provided complete relief of his radicular symptoms. However, the right hemidiaphragmatic paralysis remained at the 1-year postoperative visit. LESSONS: Thorough literature review showed no established explanations for phrenic nerve injury after CTFESI. In this study, the authors explored the suspected mechanisms of possible injury to the phrenic nerve. Epidural corticosteroid injection is considered to be a safe option for conservative management of cervical radiculopathy. This study unveiled a unique and important adverse event that should be considered before a patient receives CTFESI.